Abstract
Aminoglycosides is one of the main antimicrobial drug classes and continue to play a role in the treatment of several infections, although their relatively high rate of specific adverse reactions. Tobramycin is a typical antibiotic of this class which has a good safety profile and higher (than other aminoglycosides) activity against Pseudomonas aeruginosa (an important pathogen of severe nosocomial infections). The latter characteristic and the development of antimicrobial resistance in Pseudomonas determine the area of tobramycin use in current clinical practice. This review presents pharmacokinetics and pharmacodynamics of tobramycin as well as the results of well-designed clinical trials demonstrating its efficacy in combination with other antimicrobial agents in the treatment of life-threatening infections caused by Pseudomonas. Inhalational use of tobramycin as a potential therapy for patients with cystic fibrosis is not considered in the article.
-
1.
Piepersberg W., Wehmeier U.F. Aminoglycosides, bioactive bacterial metabolites. Encyclopedia of Microbiology 2009; 183-92.
-
2.
Lode H. Tobramycin: a review of therapeutic uses and dosing schedules. Current therapeutic research 1998; 59:420-53.
-
3.
Andriole V.T. Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin on gentamicin. J Infect Dis 1974; 129:124-33.
-
4.
Scholar E. Tobramycin. xPharm: The comprehensive pharmacology reference 2007; 1-5.
-
5.
Scholar E.M., Pratt W. Bactericidal inhibitors of protein synthesis. The aminoglycosides. In: The antimicrobial drugs. 2-ed. New York: Oxford University Press; 2000. p. 127-58.
-
6.
Tre-Hardy M., Vanderbist F., Traore H., et al. In vitro activity of antibiotic combinations against P. aeruginosa biofilm and planktonic cultures. Int J Antimicrob Agents 2008; 31:329-36.
-
7.
Babic F., Venturi V., Maravic-Vlahovicek G. Tobramycin at subinhibitory concentration inhibits the RhlI/R quorum sensing system in P. aeruginosa environmental isolate. BMC Infect Dis 2010; 2:148.
-
8.
Fujimura T., Anan N., Sugimori G., et al. Susceptibility of P. aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 2009; 34:523-8.
-
9.
Burgess D.S., Hall R.G., Hardin T.C. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against P. aeruginosa. Diagn Microbiol Infect Dis 2003; 46:131-7.
-
10.
Jones R.N., Stilwell M.G., Rhomberg P.R., et al. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY antimicrobial surveillance program (1997-2007). Diagn Microbiol Infect Dis 2009; 65:331-4.
-
11.
Козлов Р.С. Селекция резистентных микроорганизмов при использовании антимикробных препаратов: концепция «параллельного ущерба» Клин Микроб Антимикроб Химиотер 2010; 12(4):284-94.
-
12.
Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious diseases society of America and the Society for healthcare epidemiology of America Guidelines for developing an Institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
-
13.
Hibbard M.L., Kopelman T.R., O’Neill P.J., et al. Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia. Surg Infect 2010; 11:427-32.
-
14.
Akers K.S., Chaney C., Barsoumian A., et al. Aminoglycoside resistance and susceptibility testing errors in A. baumannii calcoaceticus complex. J Clin Microbiol 2010; 48:1132-8.
-
15.
Cabezudo I., Pfaller M., Bale M., et al. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of P. aeruginosa. Diagn Microbiol Infect Dis 1989; 12:337-41.
-
16.
Burgess D.S., Hall R.G. In vitro activity of parenteral beta-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum beta-lactamase producing K. pneumoniae. Int J Antimicrob Agents 2004; 24:48-52.
-
17.
Parry M.F., Neu H.C. A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for serious infection due to gram-negative bacilli. American J Medicine 1978; 64:961-6.
-
18.
Schentag J.J., Wels P.B., Reitberg D.P., et al. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin abdominal sepsis. Ann Surg 1983; 198:35-41.
-
19.
Ozbek B., Otuk G. Post-antibiotic effect of levofloxacin and tobramycin alone or in combinations with cefepime against P. aeruginosa. Chemotherapy 2009; 55:446-50.
-
20.
Dundar D., Otkun M. In vitro efficacy of synergistic antibiotic combinations in multidrug resistant P. aeruginosa strains. Yonsei Med J 2010; 51:111-6.
-
21.
Bodey G.P., Jadeja L., Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9.
-
22.
Croisier D., Martha B., Piroth L., et al. In vitro efficacy of humanized intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia. Int J Antimicrob Agents 2008; 32:494-8.
-
23.
Nicolau D.P., McNabb J., Lacy M.K., et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patient with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17:497-504.
-
24.
Eckert R., Brady K.M., Greenberg E.P., et al. Enhancement of antimicrobial activity against P. aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother 2006; 50:3833-8.
-
25.
Joshi M., Bernstein J., Solomkin J., et al. Piperacillin/ tazobactam plus tobramycin versus ceftazidime plus tobramycin for treatment of patient with nosocomial lower respiratory tract infection. J Antimicrob Chemother 1999; 43:389-97.
-
26.
Joshi M., Metzler M., McCarthy M., et al. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respiratory Medicine 2006; 100:1554-65.
-
27.
Latzin P., Fehling M., Bauernfeind A., et al. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cystic Fibrosis 2008; 7:142-6.
-
28.
Xuan D., Lu J., Nicolau D.P., et al. Population pharmacokinetics of tobramycin in hospitalized patient receiving once-daily dosing regimen. J Antimicrob Agents 2000; 15:185-91.
-
29.
Reimann I.R., Meier-Hellmann A., Traust T., et al. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patient. Exp Toxic Pathol 2003; 54:493-8.
-
30.
Buijik S., Mouton J., Gyssens I., et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Medicine 2002; 28:936-42.
-
31.
Bracco D., Landry C., Dubois M., et al. Pharmacokinetic variability of extended interval tobramycin in burn patient. Burns 2008; 34:791-6.
-
32.
Ferriols-Lisart R., Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. American J Health-System Pharmacy. 1996; 53:1141-50.
-
33.
Ali M.Z., Goetz M.B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:796-809.
-
34.
Bailey T.C., Russell Little J., Littenberg B., et al. A metaanalysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:786- 95.
-
35.
Munckhof W.J., Grayson M.L., Turnidge J.D. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645-63.
-
36.
Inclan G., Suarez E., Calvo R., et al. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates. J Antimicrob Agents 2005; 26:304-11.
-
37.
Kahlmeter G., Dahlager J.I. Aminoglycoside toxicity: a review of clinical studies published between 1875-1982. J Antimicrob Chemother 1984; 13:9-22.
-
38.
de Hoog M., van Zanten G.A., Hoeve L.J., et al. A pilot case control follow-up study on hearing in children treated with tobramycin in the newborn period. Int J Pediatr Otolaryngol 2002; 65:225-32.
-
39.
de Hoog M., van Zanten G.A., Hop W.C., et al. Newborn hearing screening. Tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142:41-6.
-
40.
Hess M., Finckh-Kramer U., Bartsch M., et al. Hearing screening in at-risk neonate cohort. Int J Pediatr Otolaryngol 1998; 46:81-9.
-
41.
Okpara A.U., Amaya-Diaz A., Egbunike I.G., et al. Evaluating once daily dosing of aminoglycosides: an observational study. Formulary 1996; 31:34-48.
-
42.
Parker S.E., Davey P.G. Once-daily aminoglycoside administration in gram-negative sepsis: economic and practical aspects. Pharmacoeconomics 1995; 7:393-402.
-
43.
Prins J.M., Koopmans R.P., Buller H.R., et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis 1995; 14:531-5.
-
44.
Plumridge R.J. Cost comparison of intravenous antibiotic administration Med J Aust 1990; 153:516-8.
-
45.
Nicolau D.P., Wu A.H., Finocchiaro S., et al. Once daily aminoglycoside dosing: impact on requests and cost for therapeutic drug monitoring. Ther Drug Monit 1996; 18:263-6.
-
46.
Mithani H., Brown G. The economic impact of oncedaily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics 1996; 10:494-503.
-
47.
Jones T.E., Peter J.V., Field J. Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients. Anaesth Intensive Care 2009; 37:944-52.